Promising Responses from Dual-Targeting CAR T-Cell Therapy in Myeloma Support Further Exploration
December 7, 2019
Chimeric antigen receptor T-cell therapy targeting both BCMA and CD38 induced an objective response in >90% of patients with multiple myeloma who had been treated with at least 3 prior therapies and whose disease had spread outside of the bone marrow.
